UBS 18/02/2010 1 Buy $41.10 20.9%
A good operational result, obscured by swine flu and plasma margin growth with profits up 23%, UBS says.
In terms of outlook, UBS feels its all about plasma and the 4-year roll out of Privigen margin improvements.
While the 1H result was, solid, the broker feels share price gains will be step by step.
credit suisse - $40.50, page-3
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.33 |
Change
3.280(1.06%) |
Mkt cap ! $150.4B | |||
| Open | High | Low | Value | Volume |
| $310.00 | $312.47 | $310.00 | $172.6M | 554.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 130 | $311.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.50 | 210 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |